Giuseppe Danilo Norata

List of Publications by Year in Descending Order

167 papers	7,189 citations	50 h-index	79 g-index
182 ext. papers	8,594 ext. citations	7 avg, IF	6.05 L-index

#	Paper	IF	Citations
167	Impact of metabolic disorders on the structural, functional, and immunological integrity of the blood-brain barrier: Therapeutic avenues.. *FASEB Journal*, **2022**, 36, e22107	0.9	3
166	Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events.. *Annals of Medicine*, **2022**, 54, 1036-1046	1.5	1
165	Lack of ApoA-I in ApoEKO Mice Causes Skin Xanthomas, Worsening of Inflammation, and Increased Coronary Atherosclerosis in the Absence of Hyperlipidemia.. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2022**, 101161ATVBAHA122317790	9.4	1
164	Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors. *Current Atherosclerosis Reports*, **2021**, 23, 79	6	3
163	Recent insights into low-density lipoprotein metabolism and therapy. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2021**, 24, 120-126	3.8	2
162	Adoptive transfer of CX3CR1 transduced-T regulatory cells improves homing to the atherosclerotic plaques and dampens atherosclerosis progression. *Cardiovascular Research*, **2021**, 117, 2069-2082	9.9	15
161	HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases. *Cells*, **2021**, 10,	7.9	6
160	A Synthetic Peptide Designed to Neutralize Lipopolysaccharides Attenuates Metaflammation and Diet-Induced Metabolic Derangements in Mice. *Frontiers in Immunology*, **2021**, 12, 701275	8.4	2
159	Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis. *Cardiovascular Research*, **2021**, 117, 29-42	9.9	53
158	Metabolic adaptations of cells at the vascular-immune interface during atherosclerosis. *Molecular Aspects of Medicine*, **2021**, 77, 100918	16.7	4
157	Impact of protein glycosylation on lipoprotein metabolism and atherosclerosis. *Cardiovascular Research*, **2021**, 117, 1033-1045	9.9	4
156	Metabolomics, Lipidomics, and Immunometabolism. *Methods in Molecular Biology*, **2021**, 2285, 319-328	1.4	1
155	Gut Microbiota Functional Dysbiosis Relates to Individual Diet in Subclinical Carotid Atherosclerosis. *Nutrients*, **2021**, 13,	6.7	7
154	Effect of Lipids and Lipoproteins on Hematopoietic Cell Metabolism and Commitment in Atherosclerosis. *Immunometabolism*, **2021**, 3, e210014	4.1	5
153	Caloric Restriction Promotes Immunometabolic Reprogramming Leading to Protection from Tuberculosis. *Cell Metabolism*, **2021**, 33, 300-318.e12	24.6	12
152	PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction. *European Heart Journal*, **2021**, 42, 3078-3090	9.5	8
151	DDASSQ: An open-source, multiple peptide sequencing strategy for label free quantification based on an OpenMS pipeline in the KNIME analytics platform. *Proteomics*, **2021**, 21, e2000319	4.8	2

150	In silico drug repurposing in COVID-19: A network-based analysis. *Biomedicine and Pharmacotherapy*, **2021**, 142, 111954	7.5	3
149	Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials. *Current Atherosclerosis Reports*, **2020**, 22, 18	6	14
148	New Pharmacological Approaches to Target PCSK9. *Current Atherosclerosis Reports*, **2020**, 22, 24	6	22
147	LDL-Cholesterol-Lowering Therapy. *Handbook of Experimental Pharmacology*, **2020**, 1	3.2	3
146	Rivaroxaban improves vascular response in LPS-induced acute inflammation in experimental models. *PLoS ONE*, **2020**, 15, e0240669	3.7	4
145	Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors. *European Journal of Preventive Cardiology*, **2020**,	3.9	2
144	P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors. *Cancer Research*, **2020**, 80, 3906-3919	10.1	16
143	Low Plasma Lecithin: Cholesterol Acyltransferase (LCAT) Concentration Predicts Chronic Kidney Disease. *Journal of Clinical Medicine*, **2020**, 9,	5.1	10
142	Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium. *European Journal of Preventive Cardiology*, **2020**, 27, 234-243	3.9	5
141	Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism. *European Heart Journal*, **2020**, 41, 2487-2497	9.5	25
140	Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. *Cardiovascular Research*, **2019**, 115, 510-518	9.9	41
139	Lysosomal Acid Lipase: From Cellular Lipid Handler to Immunometabolic Target. *Trends in Pharmacological Sciences*, **2019**, 40, 104-115	13.2	23
138	Immunometabolic function of cholesterol in cardiovascular disease and beyond. *Cardiovascular Research*, **2019**, 115, 1393-1407	9.9	30
137	Cholesterol metabolism, pancreatic β-cell function and diabetes. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2019**, 1865, 2149-2156	6.9	30
136	The Interconnection Between Immuno-Metabolism, Diabetes, and CKD. *Current Diabetes Reports*, **2019**, 19, 21	5.6	15
135	Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role in the Pathophysiology and Experimental Therapy of Type-2 Diabetes. *Frontiers in Immunology*, **2019**, 10, 571	8.4	22
134	Pentraxin 3 deficiency protects from the metabolic inflammation associated to diet-induced obesity. *Cardiovascular Research*, **2019**, 115, 1861-1872	9.9	15
133	The Role of Monocytes and Macrophages in Human Atherosclerosis, Plaque Neoangiogenesis, and Atherothrombosis. *Mediators of Inflammation*, **2019**, 2019, 7434376	4.3	45

132	PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the low-density lipoprotein receptor. *European Heart Journal*, **2019**, 40, 357-368	9.5	64
131	Biological Consequences of Dysfunctional HDL. *Current Medicinal Chemistry*, **2019**, 26, 1644-1664	4.3	34
130	Cholesterol membrane content has a ubiquitous evolutionary function in immune cell activation: the role of HDL. *Current Opinion in Lipidology*, **2019**, 30, 462-469	4.4	13
129	Zc3h10 is a novel mitochondrial regulator. *EMBO Reports*, **2018**, 19,	6.5	15
128	Trained immunity and cardiovascular disease: is it time for translation to humans?. *Cardiovascular Research*, **2018**, 114, e41-e42	9.9	4
127	The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis. *Current Atherosclerosis Reports*, **2018**, 20, 12	6	46
126	Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps. *Pharmacological Research*, **2018**, 130, 1-11	10.2	17
125	Disease trends over time and CD4CCR5 T-cells expansion predict carotid atherosclerosis development in patients with systemic lupus erythematosus. *Nutrition, Metabolism and Cardiovascular Diseases*, **2018**, 28, 53-63	4.5	19
124	Myeloid apolipoprotein E controls dendritic cell antigen presentation and T cell activation. *Nature Communications*, **2018**, 9, 3083	17.4	56
123	Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk - Results from the PROG-IMT collaboration. *PLoS ONE*, **2018**, 13, e0191172	3.7	31
122	Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: Gaps and open questions. *Nutrition, Metabolism and Cardiovascular Diseases*, **2017**, 27, 379-395	4.5	44
121	Obesity-Induced Metabolic Stress Leads to Biased Effector Memory CD4 T Cell Differentiation via PI3K p110Δ-Akt-Mediated Signals. *Cell Metabolism*, **2017**, 25, 593-609	24.6	82
120	A past and present overview of macrophage metabolism and functional outcomes. *Clinical Science*, **2017**, 131, 1329-1342	6.5	53
119	Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. *British Journal of Pharmacology*, **2017**, 174, 3973-3985	8.6	80
118	Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. *Journal of Molecular and Cellular Cardiology*, **2017**, 106, 55-67	5.8	34
117	Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?. *Molecular Therapy*, **2017**, 25, 2435-2437	11.7	1
116	Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives. *Vascular Health and Risk Management*, **2017**, 13, 343-351	4.4	11
115	Advances in Hypercholesterolemia **2017**, 663-693		1

114	Strategies for the use of nonstatin therapies. *Current Opinion in Lipidology*, **2017**, 28, 458-464	4.4	2
113	PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans. *European Journal of Preventive Cardiology*, **2017**, 24, 1870-1877	3.9	33
112	Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis. *Immunity*, **2017**, 47, 875-889.e10	32.3	99
111	Genetically determined telomeres shortening is associated with carotid atherosclerosis progression and increased incidence of cardiovascular events. *International Journal of Cardiology*, **2016**, 223, 43-45	3.2	2
110	Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. *European Journal of Preventive Cardiology*, **2016**, 23, 194-205	3.9	60
109	Normative values for carotid intima media thickness and its progression: Are they transferrable outside of their cohort of origin?. *European Journal of Preventive Cardiology*, **2016**, 23, 1165-73	3.9	22
108	Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population. *Nutrition, Metabolism and Cardiovascular Diseases*, **2016**, 26, 141-53	4.5	28
107	Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. *Atherosclerosis*, **2016**, 246, 208-13	3.1	61
106	Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. *PLoS ONE*, **2016**, 11, e0162473	3.7	34
105	Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2016**, 1862, 1182-90	6.9	27
104	Circulating CD14+ and CD14CD16- classical monocytes are reduced in patients with signs of plaque neovascularization in the carotid artery. *Atherosclerosis*, **2016**, 255, 171-178	3.1	24
103	Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. *Cardiovascular Research*, **2016**, 112, 429-42	9.9	83
102	Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment. *Immunobiology*, **2015**, 220, 1025-9	3.4	15
101	Carotid intima-media thickness progression and risk of vascular events in people with diabetes: results from the PROG-IMT collaboration. *Diabetes Care*, **2015**, 38, 1921-9	14.6	52
100	PI3K-C2□s a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling. *Nature Communications*, **2015**, 6, 7400	17.4	107
99	Apolipoprotein C-III: From Pathophysiology to Pharmacology. *Trends in Pharmacological Sciences*, **2015**, 36, 675-687	13.2	110
98	Functional Analysis of a Carotid Intima-Media Thickness Locus Implicates BCAR1 and Suggests a Causal Variant. *Circulation: Cardiovascular Genetics*, **2015**, 8, 696-706		12
97	The Cellular and Molecular Basis of Translational Immunometabolism. *Immunity*, **2015**, 43, 421-34	32.3	123

96	Impact of systemic inflammation and autoimmune diseases on apoA-I and HDL plasma levels and functions. *Handbook of Experimental Pharmacology*, **2015**, 224, 455-82	3.2	30
95	Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice. *Thrombosis and Haemostasis*, **2015**, 114, 186-97	7	19
94	Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis. *Mediators of Inflammation*, **2015**, 2015, 718329	4.3	98
93	IDOL N342S Variant, Atherosclerosis Progression and Cardiovascular Disorders in the Italian General Population. *PLoS ONE*, **2015**, 10, e0122414	3.7	9
92	An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. *Journal of Experimental Medicine*, **2015**, 212, 905-25	16.6	86
91	Telomere shortening over 6 years is associated with increased subclinical carotid vascular damage and worse cardiovascular prognosis in the general population. *Journal of Internal Medicine*, **2015**, 277, 478-87	10.8	43
90	Homozygous familial hypobetalipoproteinemia: two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature. *Atherosclerosis*, **2015**, 239, 209-17	3.1	15
89	HDL in infectious diseases and sepsis. *Handbook of Experimental Pharmacology*, **2015**, 224, 483-508	3.2	99
88	Production and Metabolism of Triglyceride-Rich Lipoproteins in Both the Normal and Diabetic States. *Contemporary Diabetes*, **2014**, 125-139	0	1
87	Statins and periodontal inflammation: a pleiotropic effect of statins or a pleiotropic effect of LDL-cholesterol lowering?. *Atherosclerosis*, **2014**, 234, 381-2	3.1	2
86	Statins and skeletal muscles toxicity: from clinical trials to everyday practice. *Pharmacological Research*, **2014**, 88, 107-13	10.2	38
85	Targeting PCSK9 for hypercholesterolemia. *Annual Review of Pharmacology and Toxicology*, **2014**, 54, 273-93	17.9	71
84	Novel concepts in HDL pharmacology. *Cardiovascular Research*, **2014**, 103, 423-8	9.9	22
83	HDL: to treat or not to treat?. *Current Atherosclerosis Reports*, **2014**, 16, 429	6	11
82	Pentraxin 3 (PTX3) plasma levels and carotid intima media thickness progression in the general population. *Nutrition, Metabolism and Cardiovascular Diseases*, **2014**, 24, 518-23	4.5	26
81	New therapeutic principles for Familial Hypercholesterolemia. *Clinical Biochemistry*, **2014**, 47, 756	3.5	
80	PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges. *Vascular Pharmacology*, **2014**, 62, 103-11	5.9	27
79	Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. *Nutrition, Metabolism and Cardiovascular Diseases*, **2014**, 24, 751-9	4.5	34

78	MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/-mice. *Thrombosis and Haemostasis*, **2014**, 112, 796-802	7	77
77	Postprandial lipemia as a cardiometabolic risk factor. *Current Medical Research and Opinion*, **2014**, 30, 1489-503	2.5	75
76	HDL in innate and adaptive immunity. *Cardiovascular Research*, **2014**, 103, 372-83	9.9	144
75	The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. *Cell Metabolism*, **2014**, 20, 787-798	24.6	72
74	The missing link between high-density lipoprotein cholesterol and inflammatory response in cardiovascular disease. *Journal of the American College of Cardiology*, **2014**, 63, 2747-8	15.1	
73	The CD1d-natural killer T cell axis in atherosclerosis. *Journal of Innate Immunity*, **2014**, 6, 3-12	6.9	15
72	Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. *European Journal of Clinical Pharmacology*, **2013**, 69, 341-6	2.8	21
71	New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. *European Heart Journal*, **2013**, 34, 1783-9	9.5	72
70	Prevalence of classical CD14++/CD16- but not of intermediate CD14++/CD16+ monocytes in hypoalphalipoproteinemia. *International Journal of Cardiology*, **2013**, 168, 2886-9	3.2	14
69	High-density lipoprotein subfractions--what the clinicians need to know. *Cardiology*, **2013**, 124, 116-25	1.6	81
68	Gene silencing approaches for the management of dyslipidaemia. *Trends in Pharmacological Sciences*, **2013**, 34, 198-205	13.2	25
67	MicroRNAs and lipoproteins: a connection beyond atherosclerosis?. *Atherosclerosis*, **2013**, 227, 209-15	3.1	31
66	Identification of seven loci affecting mean telomere length and their association with disease. *Nature Genetics*, **2013**, 45, 422-7, 427e1-2	36.3	624
65	Pharmacogenetics in cardiovascular disorders: an update on the principal drugs. *American Journal of Cardiovascular Drugs*, **2013**, 13, 79-85	4	2
64	-374 T/A RAGE polymorphism is associated with chronic kidney disease progression in subjects affected by nephrocardiovascular disease. *PLoS ONE*, **2013**, 8, e60089	3.7	10
63	LOX-1, OxLDL, and atherosclerosis. *Mediators of Inflammation*, **2013**, 2013, 152786	4.3	405
62	Long pentraxin 3: experimental and clinical relevance in cardiovascular diseases. *Mediators of Inflammation*, **2013**, 2013, 725102	4.3	67
61	High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. *Journal of Internal Medicine*, **2013**, 274, 252-62	10.8	57

60	The thyroid receptor modulator KB3495 reduces atherosclerosis independently of total cholesterol in the circulation in ApoE deficient mice. *PLoS ONE*, **2013**, 8, e78534	3.7	6
59	Class II phosphoinositide 3-kinases contribute to endothelial cells morphogenesis. *PLoS ONE*, **2013**, 8, e53808	3.7	21
58	Treating high density lipoprotein cholesterol (HDL-C): quantity versus quality. *Current Pharmaceutical Design*, **2013**, 19, 3841-57	3.3	22
57	Emerging role of high density lipoproteins as a player in the immune system. *Atherosclerosis*, **2012**, 220, 11-21	3.1	133
56	Leonurine: a new comer in the natural compounds affecting atherosclerosis. *Atherosclerosis*, **2012**, 224, 37-8	3.1	8
55	HDL and adaptive immunity: a tale of lipid rafts. *Atherosclerosis*, **2012**, 225, 34-5	3.1	17
54	Effect of Tie-2 conditional deletion of BDNF on atherosclerosis in the ApoE null mutant mouse. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2012**, 1822, 927-35	6.9	7
53	Association between OLR1 K167N SNP and intima media thickness of the common carotid artery in the general population. *PLoS ONE*, **2012**, 7, e31086	3.7	18
52	Antigen-dependent and antigen-independent pathways modulate CD4+CD28null T-cells during atherosclerosis. *Circulation Research*, **2012**, 111, e48-9; author reply e50-1	15.7	7
51	Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis. *Arteriosclerosis, Thrombosis, and Vascular Biology* , **2012**, 32, 696-703	9.4	54
50	LOX-1 Inhibition in ApoE KO Mice Using a Schizophyllan-based Antisense Oligonucleotide Therapy. *Molecular Therapy - Nucleic Acids*, **2012**, 1, e58	10.7	10
49	Established and emerging approaches for the management of dyslipidaemia. *Scientifica*, **2012**, 2012, 482423	2.6	0
48	Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models. *Journal of the American Heart Association*, **2012**, 1, 27-41	6	96
47	MicroRNA 143-145 deficiency impairs vascular function. *International Journal of Immunopathology and Pharmacology*, **2012**, 25, 467-74	3	26
46	Association between the Adherence to AHA Step 1 Nutrition Criteria and the Cardiometabolic Outcome in the General Population a Two Year Follow-Up Study. *Food and Nutrition Sciences (Print)*, **2012**, 03, 274-280	0.4	1
45	Pentraxins and Atherosclerosis **2012**, 219-237		
44	High density lipoproteins and atherosclerosis: emerging aspects. *Journal of Geriatric Cardiology*, **2012**, 9, 401-7	1.7	16
43	Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. *Nutrition, Metabolism and Cardiovascular Diseases*, **2011**, 21, 835-43	4.5	79

42	HDLs, immunity, and atherosclerosis. *Current Opinion in Lipidology*, **2011**, 22, 410-6	4.4	35
41	Novel biotinylated bile acid amphiphiles: micellar aggregates formation and interaction with hepatocytes. *Organic and Biomolecular Chemistry*, **2011**, 9, 2899-905	3.9	
40	Circulating CD4+CD25hiCD127lo regulatory T-Cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 1832-41	9.4	110
39	Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status. *Nutrition, Metabolism and Cardiovascular Diseases*, **2010**, 20, 56-63	4.5	25
38	Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): Rationale and design of a meta-analysis project. *American Heart Journal*, **2010**, 159, 730-736.e2	4.9	32
37	Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. *Atherosclerosis*, **2010**, 208, 177-82	3.1	67
36	Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. *Atherosclerosis*, **2010**, 210, 78-87	3.1	40
35	The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits tumor necrosis factor alpha and lipopolysaccharide induced inflammatory response in human endothelial cells and in mice aorta. *Atherosclerosis*, **2010**, 212, 100-6	3.1	33
34	Lecithin:cholesterol acyltransferase and vascular disease. *Clinical Lipidology*, **2010**, 5, 13-15		
33	The long pentraxin PTX3: a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases. *Trends in Cardiovascular Medicine*, **2010**, 20, 35-40	6.9	113
32	Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. *Circulation*, **2009**, 120, 699-708	16.7	225
31	Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. *Nutrition, Metabolism and Cardiovascular Diseases*, **2009**, 19, 129-34	4.5	85
30	Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. *Atherosclerosis*, **2009**, 206, 556-62	3.1	57
29	Cholesterol Absorption Inhibitors **2009**, 288-297		
28	Long pentraxin 3, a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 925-31	9.4	122
27	Combination therapy in cholesterol reduction: focus on ezetimibe and statins. *Vascular Health and Risk Management*, **2008**, 4, 267-78	4.4	17
26	Inhibition of synthesis and absorption of cholesterol: A new option in managing hypercholesterolemia. *International Congress Series*, **2007**, 1303, 121-128		1
25	Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction. *Journal of Internal Medicine*, **2007**, 262, 104-12	10.8	52

24	Leptin:adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. *Stroke*, **2007**, 38, 2844-6	6.7	142
23	Plasma resistin levels correlate with determinants of the metabolic syndrome. *European Journal of Endocrinology*, **2007**, 156, 279-84	6.5	151
22	Triglyceride-rich lipoproteins from normotrygliceridemic subjects and hyperlipidemic patients differently affect endothelial cell activation and gene expression patterns. *Circulation Research*, **2007**, 100, e81	15.7	7
21	Triglyceride-Rich Lipoproteins And Endothelial Dysfunction: Molecular Mechanisms And Gene Expression Studies. *Future Lipidology*, **2007**, 2, 119-122		
20	ApoE gene delivery inhibits severe hypercholesterolemia in newborn ApoE-KO mice. *Biochemical and Biophysical Research Communications*, **2007**, 361, 543-8	3.4	3
19	Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. *Atherosclerosis*, **2007**, 191, 265-71	3.1	125
18	Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. *Atherosclerosis*, **2007**, 193, 321-7	3.1	105
17	Molecular Mechanisms Responsible for the Anti-Inflammatory and Protective Effect of High-Density Lipoprotein on the Endothelium. *High Blood Pressure and Cardiovascular Prevention*, **2007**, 14, 21-31	2.9	1
16	Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 546-54	5.6	122
15	Effects of fractalkine receptor variants on common carotid artery intima-media thickness. *Stroke*, **2006**, 37, 1558-61	6.7	43
14	Triglyceride-rich lipoproteins from hypertriglyceridemic subjects induce a pro-inflammatory response in the endothelium: Molecular mechanisms and gene expression studies. *Journal of Molecular and Cellular Cardiology*, **2006**, 40, 484-94	5.8	45
13	Modified HDL: biological and physiopathological consequences. *Nutrition, Metabolism and Cardiovascular Diseases*, **2006**, 16, 371-86	4.5	63
12	HDL and endothelial function: from molecular mechanisms to clinical observations. *Future Lipidology*, **2006**, 1, 343-355		2
11	Oxidized-HDL3 modulates the expression of Cox-2 in human endothelial cells. *International Journal of Molecular Medicine*, **2006**, 18, 209-13	4.4	8
10	Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. *Journal of Internal Medicine*, **2005**, 258, 21-7	10.8	66
9	High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. *Circulation*, **2005**, 111, 2805-11	16.7	76
8	Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. *Vascular Health and Risk Management*, **2005**, 1, 119-29	4.4	49
7	HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2004**, 24, 871-7	9.4	85

6	Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization. *British Journal of Haematology*, **2004**, 127, 97-104	4.5	47
5	Matrix metalloproteinase-26 (matrilysin-2) expression is high in endometrial hyperplasia and decreases with loss of histological differentiation in endometrial cancer. *Gynecologic Oncology*, **2004**, 94, 661-70	4.9	24
4	High-density lipoprotein subfraction 3 decreases ADAMTS-1 expression induced by lipopolysaccharide and tumor necrosis factor-alpha in human endothelial cells. *Matrix Biology*, **2004**, 22, 557-60	11.4	29
3	Lipid lowering activity of drugs affecting cholesterol absorption. *Nutrition, Metabolism and Cardiovascular Diseases*, **2004**, 14, 42-51	4.5	11
2	Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. *Cardiovascular Research*, **2003**, 59, 169-80	9.9	50
1	Effects of HDL3 on the expression of matrix-degrading proteases in human endothelial cells. *International Journal of Molecular Medicine*, **2003**, 12, 73-8	4.4	13